TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: major thrombo-embolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients in Each Category of the Dry Eye Workshop Severity (DEWS) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defervescence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical resectability rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful Discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Mean Number of Medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electronic nose measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative complication
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle activity of rotator cuff and scapular muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of spontaneous vaginal deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Diagnostic accuracy of FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reproducibility of SUV measured with 18F-HX4 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal time frame between administration of 18F-HX4 and PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum depression symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in workplace sitting time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: biochemical recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion using device
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Discontinued Study Treatment Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Platelet Count ≤400 k/μL at Day 169
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline to Week 12 in Positive and Negative Syndrome Scale (PANSS): Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Suicidal Behavior and / or Ideation on the Columbia Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Providers Reporting Satisfaction With Technology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in social anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Self-Test Fingerstick Blood Glucose Results within specified limits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Fatigue Scale-Adolescent (FS-A) Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Safety and tolerability of AZD2423
Endpoint domain: Adverse events/effects
Primary endpoint: Amplitude integrated electroencephalography (aEEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: time-to-failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain unpleasantness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline level of problem behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Concentrations of High Density Lipoprotein Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VAS (Visual Analogical Scale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SF-36 (Short Form 36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Myalgic Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of tender points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average Knee Pain during last week
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Quadriceps isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of substance use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Logistic Organ Dysfunction (PELOD-2) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence at the anastomosis site and in the ileum
Endpoint domain: Adverse events/effects
Primary endpoint: Major Discordance Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Urinary Albumin-to-Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Colchicine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of dendrogenin A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Achieving ACR 20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in peak oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Days in Hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: rectal prolapse recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Exercise stages of change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Perceived exercise benefits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived exercise barriers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exercise preferences
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of Participants With Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social media use for disease information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in Muscle Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Maximum Voluntary Isometric Contraction (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Post-Intervention in Sport Injuries Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: CDR score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of postoperative ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mucosal impedance values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weighted mean AUC for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PSA response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response rate assessed by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Circulating 1,25-dihydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Drug Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-month PFS rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent symptomatic intracerebral hemorrhage (ICH)
Endpoint domain: Mortality/survival
Primary endpoint: improvement of dry mouth symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Crevicular Fluid Level of Malondialdehyde (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protein Carbonyl Level in Gingival Crevicular Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Antioxidant Capacity Levels in Gingival Crevicular Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Eyelash Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total hours of awake time spent in the OFF state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lead Placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: durable engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hematopoietic reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patterns of post-transplant chimerism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxidative Burst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from Atrial Fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Daily physical activity > 60 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Forced Expiratory Volume (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum ceruloplasmin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Copper Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kayser-Fleischer Rings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participant With Weight Loss ≥ 5% at the 8- Week Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with Injection site adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with Hypersensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with Post vaccination non-injection-site zoster-like and varicella-like rashes
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with Post vaccination herpes zoster occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Molecular Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers of oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grades of study product-related serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with infection with vaccine virus
Endpoint domain: Adverse events/effects
Primary endpoint: Greater than or equal to 4-fold rise in RSV-neutralizing antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-salmonella typhi Vi antigen antibody titer 2 weeks post TFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-salmonella typhi Vi antigen antibody titer 3 months post TFV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Social Network Index
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change From Baseline in Hamilton Depression Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Aberrant Behavior Checklist
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Change From Baseline in Social Responsiveness Scale-2
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change From Baseline in Ritvo Autism-Aspergers Diagnostic Scale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline in Repetitive Behavior Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Behavioral functioning
Primary endpoint: Mean change from baseline in A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hamilton Depression Scale (HAMD-17)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area under the curve of 25 OH vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decline of ALSFRS-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Month Meningitis-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Uptake of follow-up appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Immediate Clinical Efficacy on Activity Related Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term tolerance of the antivenom serum
Endpoint domain: Adverse events/effects
Primary endpoint: Response in patients with MDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of change in serum triglyceride level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Access to prenatal care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Attitudes towards clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of High PD-L1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biomarker assessment in skin biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Serum Alanine Aminotransferase Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Depression Remission
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Use of Fewer Medications That Have Potential Gene-drug Interactions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of liver stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of spleen stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of portal pressure (HVPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the number of laparoscopic ports
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of A/H5N1 Inactivated split influenza virus vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: safety as assessed by the occurrence of study related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: anti-tumor responses of CD19 CAR-T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Modification in hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Feasibility of taking nasal swabs and stool samples
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptance of taking nasal swabs and stool samples
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Arterial hypertension evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Phonological Awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Pelvic Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival (PFS) at 4 months
Endpoint domain: Mortality/survival
Primary endpoint: Allergic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Experience at Least One Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinue Study Drug Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Time-Concentration Curve (AUC 0-∞) of Montelukast CT and Montelukast OG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of vaccine primary series
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in joint swelling, pain and stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Predictive value of Doppler sonography, MR venography and air-plethysmography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fentanyl consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in 24-hour dietary recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dietary compliance (biomarkers)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness and Safety Success
Endpoint domain: Adverse events/effects
Primary endpoint: Change in fall frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urges to Self-Injure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Percent Reduction in Wound Surface Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: changes in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: dichotomous composite end point for HbA1c, weight gain, and severe hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite quantitative score from glycemic control, weight response, and degree of hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spontaneous breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of patients with a 10 fold increase of pretherapeutic minimal urticarial dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle variation in degrees measured on the Tardieu Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Scale for Suicide Ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximal platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient Tolerability and Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-operative pain 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of IO action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: time of anal exhaust and urination after gynecologic surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Endometrial Thickness of All Participants in the Mid Menstrual Measured by Color Doppler Ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wong-Baker Faces Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State-Trait Anxiety Inventory for Children
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pituitary volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change From Baseline in Cutaneous Dermatomyositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Physician's Global Assessment (PGA) Visual Acuity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes